Literature DB >> 19718632

Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.

Svetlana Karie-Guigues1, Nicolas Janus, Faouzi Saliba, Jerome Dumortier, Christophe Duvoux, Yvon Calmus, Richard Lorho, Gilbert Deray, Vincent Launay-Vacher, Georges-Philippe Pageaux.   

Abstract

The prevalence of renal insufficiency before and at 1, 12, and 60 months after liver transplantation (LTx; primary endpoint) and the changes in the glomerular filtration rate (GFR) at same time points according to the immunosuppressive regimen (coprimary endpoint) were investigated. The primary outcome was determined for the entire cohort, whereas the coprimary endpoint was determined only for 2 groups of patients: those who started and remained on a calcineurin inhibitor (CNI) alone, that is, the CNI-alone group (n = 624), and those who started and remained on a CNI in combination with mycophenolate mofetil (MMF), that is, the MMF group (n = 117). GFR was <60 mL/minute/1.73 kg/m(2) in 11%, 48%, 51% and 58% of the patients at baseline and at 1, 12, and 60 months, respectively. The decrease in GFR was significantly lower in the MMF group compared to the CNI-alone group at 12 and 60 months (-16% versus -30% and -15% versus -33%, respectively), whereas the GFR decrease at 1 month was not different between the 2 groups. There were no significant differences between the 2 groups in CNI doses or blood levels at 12 and 60 months. In conclusion, there was a worsening of renal failure in 83% of patients post-LTx; 58% and 5% had GFRs of <60 and <30 mL/minute/1.73 kg/m(2), respectively, at 5 years after LTx. The reduction of the GFR was significantly less marked in the MMF group compared to the CNI-alone group, and this could be related to less important CNI exposure early after LTx. It seems likely that early intervention for CNI reduction is best for reducing the use of CNIs in the long term. (c) 2009 AASLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718632     DOI: 10.1002/lt.21803

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

1.  Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.

Authors:  Jiu-Lin Song; Wei Gao; Yan Zhong; Lu-Nan Yan; Jia-Yin Yang; Tian-Fu Wen; Bo Li; Wen-Tao Wang; Hong Wu; Ming-Qing Xu; Zhe-Yu Chen; Yong-Gang Wei; Li Jiang; Jian Yang
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

2.  ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.

Authors:  Jun-Jun Jia; Bin-Yi Lin; Jiang-Juan He; Lei Geng; Dhruba Kadel; Li Wang; Dong-Dong Yu; Tian Shen; Zhe Yang; Yu-Fu Ye; Lin Zhou; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

3.  Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late?

Authors:  Susanne Beckebaum; Vito R Cicinnati
Journal:  Dig Dis Sci       Date:  2011-01       Impact factor: 3.199

4.  Evidence for the immunosuppressive potential of calcineurin inhibitor-sparing regimens in liver transplant recipients with impaired renal function.

Authors:  Kentaro Ide; Yuka Tanaka; Takashi Onoe; Masataka Banshodani; Hirofumi Tazawa; Yuka Igarashi; Nabin Bahadur Basnet; Marlen Doskali; Hirotaka Tashiro; Hideki Ohdan
Journal:  J Transplant       Date:  2011-07-06

5.  The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): a post-hoc between-sex analysis.

Authors:  Delia Colombo; Alessandro Zullo; Lucia Simoni; Emanuela Zagni
Journal:  BMC Nephrol       Date:  2019-12-23       Impact factor: 2.388

6.  Early tacrolimus exposure does not impact long-term outcomes after liver transplantation.

Authors:  Mikel Gastaca; Patricia Ruiz; Javier Bustamante; Lorea Martinez-Indart; Alberto Ventoso; José Ramón Fernandez; Ibone Palomares; Mikel Prieto; Milagros Testillano; Patricia Salvador; Maria Senosiain; Maria Jesus Suárez; Andres Valdivieso
Journal:  World J Hepatol       Date:  2021-03-27

7.  Short- and Long-term Outcomes of De Novo Liver Transplant Patients Treated With Once-Daily Prolonged-Release Tacrolimus.

Authors:  Yuichiro Okumura; Takehiro Noda; Hidetoshi Eguchi; Yoshifumi Iwagami; Daisaku Yamada; Tadafumi Asaoka; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Shigeru Marubashi; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Transplant Direct       Date:  2017-08-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.